title: FDA panel debates merits of next-generation opioid formulations.
authors.forename: Greg
authors.initials: G
authors.lastname: Lavine
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations; D017277:Drug Approval; D006801:Humans; D009020:Morphine / Q000008:administration & dosage / Q000737:chemistry; D009271:Naltrexone / Q000008:administration & dosage / Q000737:chemistry; D010098:Oxycodone / Q000008:administration & dosage / Q000737:chemistry; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009271:Naltrexone; D009020:Morphine; D010098:Oxycodone